Update on lead anti-cancer antibody program targeting CD44, a cancer stem
TORONTO, June 6 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced the appointment of Robert Gundel, Ph.D., MBA, to the position
of Chief Scientific Officer.
Dr. Gundel brings to ARIUS more than 25 years of experience in the
biotechnology and pharmaceutical industry. Prior to joining ARIUS, Dr. Gundel
held executive management roles at significant biopharmaceutical companies
including Bayer, Chiron, and XOMA. In his most recent role, he was Vice
President, Scientific Corporate Development at XOMA, a leader in the
discovery, development and manufacture of therapeutic antibodies. In this
role, he provided corporate leadership to key areas of XOMA's business,
including business development and specialized projects.
"The appointment of Dr. Gundel as Chief Scientific Officer is a
significant addition to the expertise of the ARIUS management team," said
Dr. David S. Young, President and Chief Executive Officer of ARIUS. "With his
strong leadership background and extensive experience in product development,
we look forward to his contributions to the advancement of our three lead
programs into human clinical trials."
Dr. Gundel holds a Ph.D. in Physiology from New York Medical College and
an MBA from St. Mary's College of California. He has published more than 60
articles in peer reviewed journals and book chapters, served on the editorial
board of several journals, and is a co-inventor on several issued U.S.
Update on ARIUS' cancer stem cell program targeting CD44
ARIUS' lead drug candidate has been transferred to a contract
manufacturer (CMO) to prepare drug supplies for human trials. Avid Biosciences
Inc., the Company's antibody manufacturer, has successfully completed scale up
in preparation for pilot toxicology studies this summer and IND enabling work.
The cancer target for this drug program, CD44, has been implicated as a cancer
stem cell marker in several cancers including breast and prostate cancers.
"The successful completion of this step represents a milestone in the
preclinical process and further emphasizes ARIUS' continuing commitment to
initiating human clinical trials in 2008," added Dr. Young.
ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusresearch.com
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
email@example.com, firstname.lastname@example.org; James Smith, Investor
Relations, (416) 815-0700 ext. 229, email@example.com